Processa Pharmaceuticals, Inc. (PCSA) Q1 2026 Annual Earnings
PCSA·Reported May 7, 2026·After market close
Diluted EPS came in at $-1.29 (-330.0% YoY), missed the $-1.00 consensus by $0.29.
Diluted EPS
$-1.29missed by $0.29
Consensus: $-1.00
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Processa Pharmaceuticals, Inc.'s Q1 2026 earnings report.
Processa Pharmaceuticals, Inc. (PCSA) reported Q1 2026 earnings on May 7, 2026 after market close.
Processa Pharmaceuticals, Inc. reported diluted EPS of $-1.29 for Q1 2026.
EPS missed the consensus estimate of $-1.00 by $0.29.
Compared to the same quarter a year prior, diluted EPS declined 330.0% from $-0.30.
You can read the 10-K/A periodic report (0001493152-26-020731) directly on SEC EDGAR. The filing index links above go to sec.gov.